.svg)
News, Research, and Obesity Insights
Stay updated with the latest research, clinical trials, and insights on Retatrutide. Explore articles on weight loss, type 2 diabetes, obesity management, and emerging therapies.
Frequently Asked Questions About Retatrutide
If you have any specific questions, feel free to reach out.
Retatrutide is a new experimental medication from the GLP-1/GIP/Glucagon agonist class, developed for the treatment of obesity and type 2 diabetes. It works by reducing appetite, slowing stomach emptying, and affecting hormones that regulate metabolism and body weight.
Retatrutide is primarily being developed for obesity treatment, with TRIUMPH trials focusing on weight loss in people with and without diabetes. It also significantly improves blood sugar control, reducing HbA1c by approximately 2% in diabetic patients, making it beneficial for both conditions.
FDA approval is expected in late 2027 or early 2028, with commercial launch following 1–3 months later. Eli Lilly must complete all seven TRIUMPH Phase 3 trials and submit a New Drug Application before the FDA's 10-month review process begins. Realistic availability: Q1–Q2 2028.
Two completed Phase 3 trials confirm retatrutide's efficacy: TRIUMPH-4 showed 28.7% average weight loss at 68 weeks, and TRIUMPH-1 confirmed 28.3% in 2,339 general obesity patients at 80 weeks. In a 104-week extension, patients reached 30.3%. This translates to approximately 70+ pounds for someone starting at 250 pounds. Results depend on dosage, diet, and exercise adherence.